Trial Profile
A Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs OTL 102 (Primary)
- Indications Chronic granulomatous disease
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 16 Nov 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2028.
- 16 Nov 2023 Planned primary completion date changed from 1 Apr 2024 to 1 Dec 2026.
- 16 Nov 2023 Status changed from active, no longer recruiting to recruiting.